Navigation Links
Eurand Announces Positive Phase III Clinical Study Results

of pills patients take each day."

Phase III Pediatric Supportive Study Results

This open label study in CF patients under the age of seven involved a seven-day dose stabilization period followed by a seven-day treatment period. The study evaluated the percentage of "responders," or those patients without excess fat in stools and without signs and symptoms of malabsorption after one and two weeks of treatment. Secondary endpoints included weight change, nutritional status, stool frequency and consistency, incidences of bloating, pain and flatulence as well as physician and parent or guardian judgment of clinical symptoms improvement.

In the study, malabsorption symptoms were significantly lower at the end of treatment than at screening, consistent with control of malabsorption symptoms with Zentase in the pivotal phase III trial.

EPI and Cystic Fibrosis

EPI is a deficiency of digestive enzymes normally produced by the pancreas. The deficiency leads to malnutrition, impaired growth in children and shortened life expectancy. EPI is commonly associated with cystic fibrosis and chronic pancreatitis.

Cystic Fibrosis affects about 30,000 individuals in the US and 100,000 worldwide. Approximately 90 percent of these individuals suffer from EPI. Treatment with PEPs helps replace enzymes lost through this disease. Other than enzyme replacement, Eurand is not aware of any other alternative therapy for EPI.

Zentase

Zentase is a zero-overfill, highly-stable, porcine-derived pancreatic enzyme replacement therapy designed to treat EPI, a deficiency of digestive enzymes normally produced by the pancreas.

Zentase closely mimics the enzyme profile of normal human pancreatic secretions. Formulated with eight key enzymes and other co-enzymes and cofactors required for proper digestion, Zentase is highly stable and requires no product overfill. The product is being developed in multiple strengths as well as a pediatric formu
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
2. Eurand to Present Zentase Phase III Data
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Eurand Announces Positive Phase III Clinical Study Results
(Date:1/23/2015)...  iMD Companies, Inc. (ICBU) has repositioned itself as a holding ... a foothold in the hydroponic, hemp and medical marijuana sectors. ... in the sector, and recently partnering with the Chippewa Tribe ... medical marijuana, iMD is committing to bring its vision to ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
(Date:1/22/2015)... Jan. 22, 2015  BiOptix is pleased to announce the ... President of Chemistry and Biochemistry. Scott joins the company after ... and Amgen throughout the course of his nearly 20 ... "Scott is a nationally recognized thought leader in the ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Oct. 21 Laureate Pharma, Inc., a full-service biopharmaceutical ... has signed a new Biopharmaceutical Development and Manufacturing Agreement ... will develop the process to manufacture a unique Fc ... for use in clinical trials. Terms of the manufacturing ...
... Inc. (Amex: UPI ) announced today that it will ... 30, 2009, at the market close on Monday, November 2, ... discuss these results on Monday, November 2, 2009 at 3:30 ... Officer, and Medi Jiwani, Vice President, Chief Financial Officer and ...
Cached Medicine Technology:Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement 2Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
(Date:1/22/2015)... 2015 EBSCO Information Services (EBSCO) ... their relationship in an effort to further promote visibility and ... EBSCO has long made AMA journals available via its subscription ... The JAMA Network. , Long known as both ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
(Date:1/22/2015)... 22, 2015 State Forestry Institute of ... system with support from GEOSYSTEMS, a dedicated Hexagon Geospatial ... will leverage Hexagon Geospatial’s ERDAS APOLLO for ... well as point clouds and documents. This effort will ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... Jan. 22 With a generous donation from Eyre Bus, Tour ... D.C. and New York areas is headed to Haiti ... Haiti Relief Committee (GWHRC) announced today.  The transport of the group is ... 11:30 p.m. tonight. , "On behalf of my father, ...
... OAKLAND , Jan. 23 After months ... hospitals and nursing homes in California , former SEIU-UHW officials ... 29 elections that are ready to proceed for more than 4,000 ... January for misusing union funds and undermining members, democratic rights, formed ...
... study says , FRIDAY, Jan. 22 (HealthDay News) -- If you,re ... to start potty training may be between the second and third ... the ideal window for moving your child out of diapers. Children ... have urge incontinence -- daytime wetting and bed-wetting -- between ages ...
... that having a conversation (for example on a cell phone) ... also true: Driving reduces one,s ability to comprehend and use ... Illinois, appear in the journal Psychonomic Bulletin & Review ... driving impairs language skills, said Gary Dell, a psycholinguist in ...
... of scientists led by Professor Adrian Krainer, Ph.D., of ... cancer cells that boost the production of an enzyme ... altered metabolic state, called the Warburg effect, promotes extremely ... Discovered eighty years ago by Nobel Prize-winning scientist Otto ...
... baby is a joyful experience. But it is not unusual ... depression. Global figures suggest that between 13 and 16 percent ... by depression. For the second birth, figures boost to a ... University of Stavanger in Norway, surveyed 250 postnatal women for ...
Cached Medicine News:Health News:Eyre Bus, Tour & Travel Donates Bus to Transport Medical Professionals from D.C. Area to New York for Flight to Haiti, Announces the Greater Washington Haiti Relief Committee and the Embassy of Haiti 2Health News:Eyre Bus, Tour & Travel Donates Bus to Transport Medical Professionals from D.C. Area to New York for Flight to Haiti, Announces the Greater Washington Haiti Relief Committee and the Embassy of Haiti 3Health News:Latest Twist: Ousted Union Officials Show True Colors By Trying to Stop 29 Union Elections 2Health News:Latest Twist: Ousted Union Officials Show True Colors By Trying to Stop 29 Union Elections 3Health News: Potty Training Best Between Ages 2 and 3 2Health News: Potty Training Best Between Ages 2 and 3 3Health News: Potty Training Best Between Ages 2 and 3 4Health News:Driven to distraction: New study shows driving hinders talking 2Health News:CSHL study identifies potential way to reverse cancer cell metabolism and tumor growth 2Health News:CSHL study identifies potential way to reverse cancer cell metabolism and tumor growth 3Health News:Emotions should be taken seriously 2Health News:Emotions should be taken seriously 3